OS
OSTX.US OS Therapies Incorporated
- Market cap
- USD 31.9M
- P/E
- -
- P/B
- 12.74x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is OSTX.US undervalued?
Graham numberThe Graham number of OS Therapies Incorporated cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OS Therapies Incorporated fundamental analysis
No fundamental analysis for OS Therapies Incorporated yet.
OS Therapies Incorporated stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH…
Full company profileOS Therapies Incorporated financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
OS Therapies Incorporated annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.25K | -1.16M | -805.00 | -4.22K | -2.78K | -363K | -500K |
| Operating Income | -5.65K | -4.84M | -4.45M | -4.34M | -6.81M | -28.7M | -37.5M |
| EBITDA | 61.4K | -4.84M | -4.45M | -4.34M | -6.83M | -28.4M | -37.3M |
| Net Income | -6.03K | -7.42M | -6.25M | -7.79M | -8.88M | -28.8M | -38.1M |
| EPS | 0.00 | -0.32 | -0.27 | -0.39 | -0.43 | -0.98 | -0.87 |
| Balance Sheet | |||||||
| Total Assets | 1.68B | 326K | 509K | 798K | 5.54M | 6.84M | 9.90B |
| Total Liabilities | 8.00B | 11.8M | 18.1M | 24.8M | 4.73M | 12.9M | 20.7B |
| Shareholders' Equity | -6.33B | -11.5M | -17.6M | -24.0M | 811K | -6.10M | -11.9B |
| Cash & Short-term Investments | 1.23B | 80.8K | 171K | 39.0K | 5.53M | 270K | 205M |
| Total Debt | 6.77B | 7.07M | 10.3M | 14.6M | 6.05M | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -2.41B | -4.40M | -3.79M | -3.01M | -7.28M | -14.2M | -20.2M |
| Capital Expenditure | 2.01M | 11.9K | 0.00 | 0.00 | 0.00 | 466K | 0.00 |
| Free Cash Flow | -2.42B | -4.41M | -3.79M | -3.01M | -7.28M | -14.2M | -20.2M |
| Ratios | |||||||
| ROE | - | - | - | - | -1,094.6% | - | - |
| ROA | 0.0% | -2,276.9% | -1,228.6% | -976.3% | -160.4% | -420.4% | -0.4% |
| Debt to Equity | - | - | - | - | 7.46x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
OS Therapies Incorporated dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 31.3M | 1.50 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns OS Therapies Incorporated
- Insiders 22.09%
- Institutions 5.59%
- Public & others 72.32%
- Shares outstanding 46.8M
- Free float 36.7M
OS Therapies Incorporated company profile
- Company name
- OS Therapies Incorporated
- Ticker
- OSTX.US
- Exchange
- USA Stocks
- Listed since
- Aug 1, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- 115 Pullman Crossing Road, Grasonville, MD, United States, 21638
- Phone
- 410 297 7793
- Website
- ostherapies.com
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
OS Therapies Incorporated management
6- Mr. Paul A. Romness M.P.H.Founder, Chairman, President & CEO · born 1966
- Dr. Robert G. Petit II, Ph.D.Chief Medical Officer & Chief Scientific Officer · born 1960
- Mr. Francis Knuettel II, M.B.A.Chief Financial Officer · born 1966
- Mr. Jack DollChief of Staff
- Mr. Gerald E. CommissiongChief Business Officer · born 1982
- Mr. Kerry M. ClemChief Commercial Officer · born 1970